Literature DB >> 35727522

Inflammation, Lymphatics, and Cardiovascular Disease: Amplification by Chronic Kidney Disease.

Valentina Kon1, Elaine L Shelton2,3, Ashley Pitzer4, Hai-Chun Yang2,5, Annet Kirabo6.   

Abstract

PURPOSE OF REVIEW: Kidney disease is a strong modulator of the composition and metabolism of the intestinal microbiome that produces toxins and inflammatory factors. The primary pathways for these harmful factors are blood vessels and nerves. Although lymphatic vessels are responsible for clearance of interstitial fluids, macromolecules, and cells, little is known about whether and how kidney injury impacts the intestinal lymphatic network. RECENT
FINDINGS: Kidney injury stimulates intestinal lymphangiogenesis, activates lymphatic endothelial cells, and increases mesenteric lymph flow. The mesenteric lymph of kidney-injured animals contains increased levels of cytokines, immune cells, isolevuglandin (IsoLG), a highly reactive dicarbonyl, and of apolipoprotein AI (apoAI). IsoLG is increased in the ileum of kidney injured animals, and intestinal epithelial cells exposed to myeloperoxidase produce more IsoLG. IsoLG-modified apoAI directly increases lymphatic vessel contractions and activates lymphatic endothelial cells. Inhibition of IsoLG by carbonyl scavenger treatment reduces intestinal lymphangiogenesis in kidney-injured animals. Research from our group and others suggests a novel mediator (IsoLG-modified apoAI) and a new pathway (intestinal lymphatic network) in the cross talk between kidneys and intestines and heart. Kidney injury activates intestinal lymphangiogenesis and increases lymphatic flow via mechanisms involving intestinally generated IsoLG. The data identify a new pathway in the kidney gut-heart axis and present a new target for kidney disease-induced intestinal disruptions that may lessen the major adverse consequence of kidney impairment, namely cardiovascular disease.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Chronic kidney disease; Immune activation; Intestines; Isolevuglandins; Lymphatics

Year:  2022        PMID: 35727522     DOI: 10.1007/s11906-022-01206-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   4.592


  57 in total

Review 1.  Monocyte trafficking across the vessel wall.

Authors:  Teresa Gerhardt; Klaus Ley
Journal:  Cardiovasc Res       Date:  2015-05-19       Impact factor: 10.787

Review 2.  The NLRP3 inflammasome in acute myocardial infarction.

Authors:  Stefano Toldo; Antonio Abbate
Journal:  Nat Rev Cardiol       Date:  2017-11-16       Impact factor: 32.419

3.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

Review 4.  Reappraising the role of inflammation in heart failure.

Authors:  Luigi Adamo; Cibele Rocha-Resende; Sumanth D Prabhu; Douglas L Mann
Journal:  Nat Rev Cardiol       Date:  2020-01-22       Impact factor: 32.419

5.  Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

Authors:  A Deswal; N J Petersen; A M Feldman; J B Young; B G White; D L Mann
Journal:  Circulation       Date:  2001-04-24       Impact factor: 29.690

6.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.

Authors:  Jean-Claude Tardif; Simon Kouz; David D Waters; Olivier F Bertrand; Rafael Diaz; Aldo P Maggioni; Fausto J Pinto; Reda Ibrahim; Habib Gamra; Ghassan S Kiwan; Colin Berry; José López-Sendón; Petr Ostadal; Wolfgang Koenig; Denis Angoulvant; Jean C Grégoire; Marc-André Lavoie; Marie-Pierre Dubé; David Rhainds; Mylène Provencher; Lucie Blondeau; Andreas Orfanos; Philippe L L'Allier; Marie-Claude Guertin; François Roubille
Journal:  N Engl J Med       Date:  2019-11-16       Impact factor: 91.245

7.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Authors:  Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

8.  Colchicine in Patients with Chronic Coronary Disease.

Authors:  Stefan M Nidorf; Aernoud T L Fiolet; Arend Mosterd; John W Eikelboom; Astrid Schut; Tjerk S J Opstal; Salem H K The; Xiao-Fang Xu; Mark A Ireland; Timo Lenderink; Donald Latchem; Pieter Hoogslag; Anastazia Jerzewski; Peter Nierop; Alan Whelan; Randall Hendriks; Henk Swart; Jeroen Schaap; Aaf F M Kuijper; Maarten W J van Hessen; Pradyot Saklani; Isabel Tan; Angus G Thompson; Allison Morton; Chris Judkins; Willem A Bax; Maurits Dirksen; Marco Alings; Graeme J Hankey; Charley A Budgeon; Jan G P Tijssen; Jan H Cornel; Peter L Thompson
Journal:  N Engl J Med       Date:  2020-08-31       Impact factor: 91.245

Review 9.  Leukocytes Link Local and Systemic Inflammation in Ischemic Cardiovascular Disease: An Expanded "Cardiovascular Continuum".

Authors:  Peter Libby; Matthias Nahrendorf; Filip K Swirski
Journal:  J Am Coll Cardiol       Date:  2016-03-08       Impact factor: 24.094

Review 10.  Inflammation and cardiovascular diseases: lessons from seminal clinical trials.

Authors:  Luca Liberale; Fabrizio Montecucco; Lena Schwarz; Thomas F Lüscher; Giovanni G Camici
Journal:  Cardiovasc Res       Date:  2021-01-21       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.